NIH Seeks Information on Optimizing Funding Policies and Other Strategies to Improve the Impact and Sustainability of Biomedical Research
The NIH has released a request for information soliciting input on the possible development of new policies and strategies to improve the impact and sustainability of its funded biomedical research enterprise. ASH members are encouraged to submit comments in response to this request.
CMS Issues Guidance on Biosimilar Reimbursement and Formulary Policy
On March 30, the
Centers for Medicare & Medicaid Services (CMS) issued two documents on Medicare
Part B and Part D payment for biosimilars that are relevant to hematology. On March 6, 2015, the FDA)approved filgrastim-sndz (ZARXIO Injection, Sandoz Inc.),
as a biosimilar to U.S.-licensed Neupogen, which is important to hematologic
therapy. Some of the most important
regimens for the treatment of patients with
hematologic disorders are biologic, so the release of this information is helpful for the field.
IOM National Cancer Policy Forum Releases a Report on Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies
The Institute of Medicine National Cancer Policy Forum (IOM NCPF) has released a summary report on a workshop it hosted on November 10, 2014, titled "Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies." This report highlights the numerous challenges raised by workshop participants on the development of biomarker tests, implementation of cancer therapies into the clinic, clinical trial structure and reimbursement issues related to molecular profiling tests.
New SGR Bill Released
On March 19, the House of Representatives introduced a bill that would permanently address the SGR issue. This bill largely follows the
policy of the bill that was introduced by the committees of jurisdiction during
the last Congress. That bill, which ASH
supported, eliminated the SGR update formula in favor of a new payment schedule. Follow the link above to read more about the bill.